172 related articles for article (PubMed ID: 11488428)
1. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages.
Tanaka K; Yasuhara M; Suzumura K; Narita H; Suzuki T
Jpn J Pharmacol; 2001 Jul; 86(3):289-96. PubMed ID: 11488428
[TBL] [Abstract][Full Text] [Related]
2. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
Bernini F; Didoni G; Bonfadini G; Bellosta S; Fumagalli R
Atherosclerosis; 1993 Dec; 104(1-2):19-26. PubMed ID: 8141843
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages.
Bernini F; Scurati N; Bonfadini G; Fumagalli R
Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1352-8. PubMed ID: 7670949
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein.
Suzumura K; Tanaka K; Yasuhara M; Narita H
Biol Pharm Bull; 2000 Jul; 23(7):873-8. PubMed ID: 10919369
[TBL] [Abstract][Full Text] [Related]
5. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
[TBL] [Abstract][Full Text] [Related]
6. Functional evidence for anti-oxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta.
Kagota S; Yamaguchi Y; Nakamura K; Kunitomo M
Clin Exp Pharmacol Physiol; 2000; 27(5-6):401-5. PubMed ID: 10831243
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation.
Suzumura K; Odawara A; Yasuhara M; Tanaka K; Narita H; Suzuki T
Biol Pharm Bull; 1999 Sep; 22(9):971-4. PubMed ID: 10513623
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin reduces modification of low-density lipoprotein in hyperlipidemic rabbit loaded with oxidative stress.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Eur J Pharmacol; 2002 Feb; 436(1-2):97-105. PubMed ID: 11834252
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
Aoki S; Ikeda K; Yamamura M; Kojo S
Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.
Suzumura K; Yasuhara M; Tanaka K; Suzuki T
Biochem Pharmacol; 1999 Mar; 57(6):697-703. PubMed ID: 10037456
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic effects of statins in atherosclerosis and diabetes.
Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits.
Yasuhara M; Suzumura K; Tanaka K; Takahashi M; Aoki S; Odawara A; Narita H; Suzuki T
Biol Pharm Bull; 2000 May; 23(5):570-4. PubMed ID: 10823666
[TBL] [Abstract][Full Text] [Related]
14. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
Hussein O; Schlezinger S; Rosenblat M; Keidar S; Aviram M
Atherosclerosis; 1997 Jan; 128(1):11-8. PubMed ID: 9051193
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G
Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953
[TBL] [Abstract][Full Text] [Related]
16. Direct effects of statins on the vascular wall.
Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
Keidar S; Aviram M; Maor I; Oiknine J; Brook JG
Br J Clin Pharmacol; 1994 Dec; 38(6):513-9. PubMed ID: 7888289
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin: effects beyond cholesterol lowering.
Corsini A
J Cardiovasc Pharmacol Ther; 2000 Jul; 5(3):161-75. PubMed ID: 11150405
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
